IACM 2020
In cooperation with AMMCan
VIRTUAL CANNABIS CONFERENCE
WEBINAR SERIES IN OCTOBER 2020
LIVE-STREAMED CONFERENCE
05 – 07 NOVEMBER 2020

The 1st virtual cannabis conference
Be part of this pioneering journey

SPONSORING & EXHIBITION INVITATION
Reasons to attend

#1
This is the first virtual cannabis conference, and a chance to be a part of a pioneering journey with an industry built on innovation and progress.

Be seen by thousands of virtual delegates from around the world. Frequent updates will attract high-quality traffic for an extended period of time.

An opportunity to build new relationships and catch up with existing customers, showcase your area of expertise! An excellent opportunity to interact with key opinion makers from around the world.

Do not miss the chance to maximize your marketing results with effective sponsorship packages during the IACM congress - build brand awareness and deliver your message to your target group.

Give your company and your products visibility by supporting IACM, the world’s foremost professional organisation dedicated to education and understanding of cannabinoid treatments.

Table of Contents

IACM goes virtual! ........................................ 4
IACM Society Profile ................................. 5
Important Contacts ................................. 6
Important Dates and Deadlines ................. 6
 Speakers .................................................. 7
Session Plan and Registration Fees ........... 12
Sponsorship Levels ................................. 14
Booth Functions ....................................... 15
Booth Visuals .......................................... 16
Sponsorship Opportunities ...................... 18
Rules and Regulations ............................. 18
Save the Date - IACM 2021 Conference ....... 19
Dear Sponsors,

In the light of COVID-19, the International Association for Cannabinoid Medicines (IACM) will organise an on-demand webinar series in the autumn of 2020. The series is followed by the 11th Conference for Cannabinoid Medicines (5-7 November) which is organised jointly with AMMCann (Asociación Mexicana de Medicina Cannabinoide) – IACM’s partner organisation in Mexico. The conference will be streamed live on the same virtual platform.

Besides the high quality programme, presented by global experts & pioneers in the field of medical cannabinoids, IACM will provide a sophisticated virtual exhibition hall where sponsors can seamlessly upload content and interact with participants. For more information please refer to the sponsoring packages in this brochure or contact our designated team.

We would be happy to welcome you as a Sponsor.

With kind regards,
Your organizing committee
Franjo Grotenhermen, IACM
Kirsten Müller-Vahl, IACM
Luis David Suárez Rodríguez, AMMCann

Two decades of IACM - 20 years of supporting research and activities towards the medicinal use of cannabis and cannabinoids

Emerged from the German Association for Cannabis as Medicine (ACM) a handful of enthusiastic medical doctors from Germany, Switzerland and Austria supported by experts from other countries founded the International Association for Cannabinoid Medicines (IACM) in March 2000. During the past 20 years until today, it evolved towards the most important scientific society for clinical research in the field of cannabis-based medicines.

The overarching aim of the IACM is to advance the knowledge on cannabis, cannabinoids, the endocannabinoid system and related topics especially with regard to their therapeutic potential, which would allow more patients to profit from a treatment with cannabis-based medicines and ease legislators to adopt their policies.

In order to reach this goal, the IACM organizes international scientific conferences, biweekly publishes the IACM-Bulletin - currently in six different languages - reaching more than 5000 people worldwide, and is working closely together with patient associations, international partner organizations and IACM ambassadors. Since 2019, the journal Cannabis and Cannabinoid Research is the official journal of the IACM. There is also a partnership with the journal Medical Cannabis and Cannabinoids.
Important Dates & Deadlines

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 July</td>
<td>Registration opens</td>
</tr>
<tr>
<td>30 July</td>
<td>Deadline: Call for abstracts (oral presentations)</td>
</tr>
<tr>
<td>Calender Week 33</td>
<td>Technical tutorial for sponsors: How to build your virtual booth</td>
</tr>
<tr>
<td>18 August</td>
<td>Virtual exhibition accessible for Sponsors</td>
</tr>
<tr>
<td>30 September</td>
<td>Deadline: Call for abstracts (posters)</td>
</tr>
<tr>
<td>05 October</td>
<td><strong>Start of Webinar Series</strong></td>
</tr>
<tr>
<td>30 October</td>
<td>Deadline: Making modifications to abstracts</td>
</tr>
<tr>
<td>05 November</td>
<td><strong>Start of 11th IACM Conference (organised jointly with AMMCann)</strong></td>
</tr>
<tr>
<td>15 December</td>
<td>End of virtual exhibition</td>
</tr>
</tbody>
</table>

Exhibition & Sponsorship

c/o Congrex Switzerland Ltd.
Reinacherstrasse 131
4053 Basel / Switzerland

T +41 61 686 77 96
F +41 61 686 77 88
E industry.iacm@congrex.com

Important Contacts

Congress Secretariat
c/o Congrex Switzerland Ltd.
Reinacherstrasse 131
4053 Basel / Switzerland

T +41 61 686 77 98
F +41 61 686 77 88
E iacm@congrex.com

Exhibition & Sponsorship
c/o Congrex Switzerland Ltd.
Reinacherstrasse 131
4053 Basel / Switzerland

T +41 61 686 77 96
F +41 61 686 77 88
E industry.iacm@congrex.com

Important Contacts

Donald I. Abrams, MD is an oncologist and Professor of Clinical Medicine at the University of California San Francisco. He has been studying the health effects of botanical cannabis since 1997. He was a member of the National Academies of Sciences, Engineering and Medicine’s committee that produced The Health Effects of Cannabis and Cannabinoids, published in 2017.

Dr. Abrams was a member of the International Association of Cannabinoid Medicine’s Executive Board for many years and was the 2007 recipient of the IACM Award for Clinical Research.

Alionka Citlali Angeles is an Industrial Pharmaceutical Chemist who graduated from the National School of Biological Sciences of the IPN. She has worked in the pharmaceutical industry in the implementation of Quality Systems, as well as in the monitoring of clinical studies. In 2000 she acted as a founder of the Clinical Pharmacology Research Service of the General Hospital of Mexico (Third party authorized for Bioequivalence studies), where she served as Quality Assurance Coordinator until 2010.

Within her activities in Authorized Third Parties she has participated in the design, conduct of the clinical phase, analytical phase of around 750 bioequivalence studies (pharmacokinetics in the Mexican population); which has made her one of the most experienced professionals in the field.

Dr. Paola Cubillos is an integrative physician, graduated from the Universidad del Rosario in Colombia, and postgraduated from the Canadian College of Naturopathic Medicine in Canada.

In recent years, she has focused her efforts on expanding the knowledge base regarding evidence-based applications of medical cannabis and is an international speaker on such issues.

Dr. Cubillos is the Medical Director for Colombia of CB2 Insights, as well as a member of the Research Ethics Committee of the Canadian College of Naturopathic Medicine, a member of the International Consortium for Research on Cannabinoids and a member of the Board of Directors of the Colombian Medical Association of Medical Cannabis.
**Boni Goldstein, MD** is the Medical Director of Canna-Centers Wellness and Education, a Los Angeles-based medical practice devoted to helping patients use cannabis for serious and chronic medical conditions. After years of working in the specialty of Pediatric Emergency medicine, she developed an interest in the science of medical cannabis after witnessing its beneficial effects in an ill friend.

Since then Dr. Goldstein has evaluated thousands of patients for its use, with a focus on treating children with intractable epilepsy, autism, and cancer. Her book *Cannabis is Medicine* will be published in September 2020.

**Franjo Grotenhermen** is Executive Director of the German Arbeitsgemeinschaft Cannabis als Medizin (ACM), Executive Director of the International Association for Cannabinoid Medicines (IACM), co-owner of Endoxo GmbH (founded in 2019) and Head of Scientific Committee of MYCB1 (since 2019).

Furthermore, he is Honorary President of the Union Francophone pour les Cannabinoides en Médecine (UFCM) and member of the Scientific Advisory Board of Portugal Medical Cannabis (PTMC). He has received the following awards: Hemp Prize 1999 of Cannabusiness, IACM 2011 Special Award, ICBC 2018 Lifetime Achievement Award, Robert Newman Memorial Prize 2018 of Akzept eV.

**Francisco Guimarães** graduated in Medicine and obtained his PhD in Pharmacology at the Medical School of Ribeirão Preto, Brazil. He then completed his post-doc at the Neuroscience and Psychiatric Unit at Manchester University, UK. In 2007 he became a Full Professor at the Department of Pharmacology, Medical School of Ribeirão Preto, University of São Paulo.

His current research is aimed at investigating the role of atypical neurotransmitters (nitric oxide and endocannabinoids) in anxiety and mood control and the effects of cannabidiol, a non-psychotomimetic component on Cannabinoid sativa, in neuropsychiatric disorders. He is a member of the Brazilian Academy of Science and has already published 289 full papers, 32 book chapters, 2 books and supervised more than 50 successful postgraduate students.

**Manuel Guzmán** is a Professor of Biochemistry and Molecular Biology at Madrid Complutense University. His research work has made it possible to characterize new effects and signaling pathways evoked by cannabinoid receptors, as well as putting forward new physiopathological implications derived from them.

Guzmán has published 150 scientific articles and has 7 patents, and has supervised 20 PhD theses. He is an Academic Member of The Spanish Royal Academy of Pharmacy, as well as a member of the Board of Directors of the IACM.

**Fernando Márquez** is a Surgeon graduated from the Universidad Autónoma del Estado de Hidalgo and currently acts as Medical Specialist in Occupational Health as well as Medical Director at CannaMed Pachuca, performing clinical research activities in cannabinoids, developing medical care protocols for patients with Parkinson’s disease, Multiple Sclerosis, Epilepsy, Cancer, Chronic Pain.

Furthermore he is a member of Cannapuertas A.C., medical staff and already was a speaker at different conferences, mainly focusing on topics like: “Cannabis and Pain”, “News on the use of Cannabis in Oncology” or “Ancestral Uses of Cannabis”.

**Raphael Mechoulam** studied biochemistry at the Hebrew University and the Weizmann Institute. He acted as senior lecturer, associate and full professor and also as rector of the Hebrew University. In 2000 he retired but continued his research on the chemistry of natural products.

Mechoulam published about 450 scientific papers and received numerous national and international prizes. Furthermore, he was granted honorary Ph.D.’s from several universities in America and Europe.

**Dr. Kirsten Müller-Vahl, M.D.**, is a Professor of Psychiatry at the Hannover Medical School (MHH). She is the head of the Tourette syndrome outpatient department at the MHH, the first Chairwoman of the ACM and a founding member as well as the first Chairwoman of the IACM.

Since 2016 Dr. Müller-Vahl has been member of the committee of experts for narcotic drugs at the federal opium bureau of the Federal Institute for Drugs and Medical Devices (BfArM) in Germany. In 2017 she received the IACM Award for Clinical Research for her special achievements regarding the re-introduction of cannabis and cannabinoids as medicine.

**Prof. Eric Murillo-Rodríguez** is a Psychologist and holds a PhD in Biomedical Sciences. Upon graduation, he completed his postdoctoral training at Harvard Medical School and was working as Associate Researcher at Cellular Physiology Institute at UNAM. Currently he holds a Full Professor position at School of Medicine Anahuac Mayab University.

His contributions include over 90 peer-reviewed publications, 18 chapters in books and 7 published books as Editor. He is an active member of several scientific societies and participates as editorial board member in various journals, including PLoS One, Brain Research, Frontiers in Neuroscience.

Prof. Murillo-Rodríguez was awarded the “Young Investigator Award” by the World Federation of Sleep Research Societies in 2003 and the “Young Investigator Honorable Mention” by the Sleep Research Society in 2004.
Roger Pertwee MA, D.Phil, DSc. (Oxford) is an Emeritus Professor at the University of Aberdeen, an Honorary Fellow of the British Pharmacological Society (BPS) and has served as President of the International Cannabinoid Research Society (ICRS) as well as as Chairman of the IACM.

Doctor Pertwee was awarded the 2002 Mechoulam Award and the 2018 Lifetime Achievement Award from the ICRS, the 2011 Wellcome Gold Medal "for outstanding contributions to pharmacology, and the 2013 IACM Special Award and a 2018 and 2019 Highly Cited Researcher Award from Clarivate Analytics in recognition of the production of Pharmacology papers ranking in the top 1% by citations.

Dr. Raquel Peyraube is a Doctor of Medicine who graduated from the University of the Republic of Uruguay. She is a specialist in Endocannabinology and Problem Drug Use. In her career, she has been involved in education, prevention, treatment and harm reduction related to drug use, including innovative theoretical-methodological developments with particular emphasis on ethical aspects. Currently, she is an ad hoc advisor to political actors, parliamentarians and government agencies in different countries.

Furthermore, Dr. Peyraube is engaged in clinical practice in Endocannabinology, research protocol development, medical education of academic standard. She is the founder and first president of the Uruguayan Society of Endocannabinology and, among others, member of the Executive Committee of the IACM and member of the Editorial Committee of the scientific journal Medical Cannabis and Cannabinoids.

Daniele Piomelli studied pharmacology and neuroscience at Columbia and at Rockefeller University. Now he works at the University of California where he acts as Louise Turner Arnold Chair in Neurosciences and Distinguished Professor of Anatomy and Neurobiology, Pharmaceutical Sciences and Biological Chemistry. Daniele has written more than 400 peer-reviewed articles, three full-length books, and has thirty-four patents.

He founded the department of drug discovery and development at the Italian Institute of Technology and three biopharmaceutical start-ups. Furthermore, he codirects the UCI’s Center for the Study of Cannabis and is Editor-in-Chief of the peer-reviewed journal, Cannabis and Cannabinoid Research.

Dr. Sari Pruchi Sagiv has over 15 years of experience in various aspects of pharmaceutical development including discovery, regulatory affairs, IP, business development and clinical trials. She serves as Director of Tech Transfer at Mor Research Applications (Clalit Health Services commercializing arm), where she is responsible for raising capital via strategic partnerships for early stage pharma technologies.

Dr. Prutchi-Sagiv has lead scientific operations in multiple cannabis-based drug companies including Kalytera, Talent Biotechs and BOL Pharma. At Gynica she is responsible for the development of cannabis-based solutions in the women’s health field.

Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Founder/CEO of CReDO Science. Previously he was Director of Research and Development for the International Cannabis and Cannabinoids Institute, 2017-19, Medical Director of PHYTECS, 2015-2017, and from 2003-2014, Senior Medical Advisor, medical monitor/study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® and Epidiolex®.

Dr. Russo is author/editor of seven books and has published more than 50 peer-reviewed articles.

Dr. Oscar Prospéro García is a Surgeon, Master in Psychology, Doctor in Neurosciences and Cognitive Behavioral Therapist. Currently he is a full-time researcher in the Department of Physiology, Faculty of Medicine, UNAM, where he directs the Cannabinoid Laboratory. He is co-discoverer of 2 brain molecules, Cortishtine and Oleamide and the author of 106 original research articles which have received more than 3,000 citations. He has published 49 reviews and 40 chapters in books of national and international circulation.

Dr. Prospéro García has been a founding member and president of the Mexican Society for Sleep Research and Medicine (SOMIMS), where he currently acts as honorary president. Furthermore, he has been distinguished as an honorary member of the Mexican Psychiatric Association (APM).
Session Plan & Registration Fees

Webinars (on demand)
October 2020

<table>
<thead>
<tr>
<th>No</th>
<th>Type</th>
<th>Name</th>
<th>Title</th>
<th>Release</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Debate</td>
<td>Frans Grotenhuis &amp; Bonni Goldstein</td>
<td>How to start a treatment with cannabis and cannabinoids</td>
<td>Calendar Week 41</td>
</tr>
<tr>
<td>2</td>
<td>Presentation</td>
<td>Raphael Mechoulam</td>
<td>A Look Back and Ahead</td>
<td>Calendar Week 42</td>
</tr>
<tr>
<td>3</td>
<td>Presentation</td>
<td>Daniele Piomelli</td>
<td>Overview of the Endocannabinoid System</td>
<td>Calendar Week 43</td>
</tr>
<tr>
<td>4</td>
<td>Presentation</td>
<td>Ethan Russo</td>
<td>Plants and the Endocannabinoid System</td>
<td>Calendar Week 44</td>
</tr>
<tr>
<td>5</td>
<td>Debate</td>
<td>Donald Abrams &amp; Manuel Guzmán</td>
<td>Cannabis in cancer</td>
<td>Calendar Week 45</td>
</tr>
<tr>
<td>6</td>
<td>Presentation</td>
<td>Kirsten Müller-Vahl</td>
<td>Cannabinoids in psychiatric disorders</td>
<td>Calendar Week 46</td>
</tr>
<tr>
<td>7</td>
<td>Presentation</td>
<td>Roger Pertwee</td>
<td>Potential therapeutic uses of certain cannabinoid-derived and synthetic cannabinoids revealed by their pharmacological properties</td>
<td>Calendar Week 47</td>
</tr>
</tbody>
</table>

Webinars will be available in multiple languages including English, French, German, Spanish & Portuguese.

11th Conference on Cannabinoids in Medicine – organised jointly with AMMCann (live stream)
5 - 7 November 2020
- CDT (Mexico City) 8am - 1.30pm
- CET (Berlin) 3pm - 8.30pm

Selected Topics
- CBD in anxiety disorders
- Cannabinoids and cancer
- Pediatric epilepsy/autism
- The challenges of running clinical trials in the cannabis space
- Effects of cannabinoids in psychiatric diseases
- Interactions and side effects
- R&D on cannabinoids for women’s health
- Potential therapeutic uses

Registration fees for webinars and conference

<table>
<thead>
<tr>
<th>Category</th>
<th>Webinar Series</th>
<th>11th Conference on Cannabinoids in Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>IACM / AMMCann* (Regular)</td>
<td>Free registration</td>
<td>EUR 160.00</td>
</tr>
<tr>
<td>IACM / AMMCann* (Student)</td>
<td>Free Registration</td>
<td>EUR 80.00</td>
</tr>
<tr>
<td>IACM Member (Regular: Hinari**)</td>
<td>Free registration</td>
<td>EUR 100.00</td>
</tr>
<tr>
<td>IACM Member (Student: Hinari**)</td>
<td>Free Registration</td>
<td>EUR 50.00</td>
</tr>
<tr>
<td>Non-Member (Regular)</td>
<td>EUR 120.00 (series) EUR 40.00 (single webinar)</td>
<td>EUR 250.00</td>
</tr>
<tr>
<td>Non-Member (Student)</td>
<td>EUR 60.00 EUR 20.00 (single webinar)</td>
<td>EUR 125.00</td>
</tr>
<tr>
<td>Non-Member (Regular: Hinari**)</td>
<td>EUR 75.00 EUR 25.00 (single webinar)</td>
<td>EUR 155.00</td>
</tr>
<tr>
<td>Non-Member (Student: Hinari**)</td>
<td>EUR 35.00 EUR 15.00 (single webinar)</td>
<td>EUR 75.00</td>
</tr>
</tbody>
</table>

Day passes (for conference only)

<table>
<thead>
<tr>
<th>Category</th>
<th>11th Conference on Cannabinoids in Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>IACM / AMMCann* (Regular)</td>
<td>EUR 80.00</td>
</tr>
<tr>
<td>IACM / AMMCann* (Student)</td>
<td>EUR 40.00</td>
</tr>
<tr>
<td>IACM Member (Regular: Hinari**)</td>
<td>EUR 50.00</td>
</tr>
<tr>
<td>IACM Member (Student: Hinari**)</td>
<td>EUR 25.00</td>
</tr>
<tr>
<td>Non-Member (Regular)</td>
<td>EUR 125.00</td>
</tr>
<tr>
<td>Non-Member (Student)</td>
<td>EUR 60.00</td>
</tr>
<tr>
<td>Non-Member (Regular: Hinari**)</td>
<td>EUR 75.00</td>
</tr>
<tr>
<td>Non-Member (Student: Hinari**)</td>
<td>EUR 35.00</td>
</tr>
</tbody>
</table>

IACM membership fee is €120/year. By becoming an IACM member right now, you will be able to enjoy all the advantages of an IACM membership including free registration for webinars and reduced fees for our conferences:
new.cannabis-med.org/m/en/membership
*AMMCann membership applies for Mexican residents only:
ammcann.org/affiliate/
**Please refer to the website below to view the list of Hinari countries
www.who.int/hinari/eligibility/en/
# Sponsorship Levels

<table>
<thead>
<tr>
<th>SPONSORSHIP LEVEL</th>
<th>AMOUNT OF TOTAL CONTRIBUTION</th>
<th>INCLUDED BENEFITS AND ACKNOWLEDGEMENTS</th>
</tr>
</thead>
</table>
| **PLATINUM SPONSORS** | EUR 15,000 | - Virtual Booth (large)  
- Logo in opening credits of webinars*  
- Logo in the lobby of the virtual exhibition*  
- Logo on banner in virtual exhibition hall*  
- Logo on IACM website*  
- Use of the congress logo for own advertisement  
- 6 complementary full delegate registrations  
- Data Metrics (according to GDPR guidelines of IACM)  
- Right to hold a Sponsoring Symposia in main session room  
- Right to hold a Poster presentation in poster area |
| **GOLD SPONSORS** | EUR 10,000 | - Virtual Booth (medium)  
- Logo in the lobby of the virtual exhibition*  
- Logo on the IACM website*  
- Use of the congress logo for own advertisement.  
- 4 complementary full delegate registrations  
- Data Metrics (according to GDPR guidelines of IACM)  
- Right to hold a Poster presentation in poster area |
| **SILVER SPONSORS** | EUR 5,000 | - Virtual Booth (small)  
- Logo on the IACM website  
- Use of the congress logo for own advertisement.  
- 2 complementary full delegate registrations  
- Right to hold a Poster presentation in poster area |

* Deep linked to your personal booth

---

# Booth functions and additional items

<table>
<thead>
<tr>
<th>Platinum</th>
<th>Gold</th>
<th>Silver</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priority placement virtual exhibition</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Number of interactive screens</td>
<td>4 Screens</td>
<td>3 Screens</td>
</tr>
<tr>
<td>Priority support booth construction</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Possibility to modify template</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Upload of PDF / Video / Html / Images / Sound / Links</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Chat function</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Possibility to modify booth template</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Colour Change Booth</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Tracking &amp; Metrics (According to IACM’s GDPR Guidelines)</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Interlink between 2 sections of booth areas, if needed</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Broadcast message on booth</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Create pop up content, chat and surveys upon entry of attendee</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Business card swipe to request a meeting</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Create and host surveys</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Representative dashboard</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Assignment of room representative</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Doorbell ring when someone enters the booth</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Receive e-mails at the booth when not available</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Virtual bag insert</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Social Media</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Booth available and visible until 15th December 2020</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Additional networking room “Terrace”</td>
<td>EUR 2,000.00</td>
<td></td>
</tr>
<tr>
<td>Industry symposia (30 min)</td>
<td>EUR 10,000.00</td>
<td></td>
</tr>
<tr>
<td>Industry symposia (15 min)</td>
<td>EUR 7,500.00</td>
<td></td>
</tr>
<tr>
<td>Poster Presentation</td>
<td>EUR 2,000.00</td>
<td></td>
</tr>
<tr>
<td>Scheduled broadcast message (former “E-Blast”) in main rooms available to all visitors</td>
<td>EUR 2,000.00</td>
<td></td>
</tr>
<tr>
<td>Customize booth</td>
<td>EUR 2,000.00</td>
<td></td>
</tr>
</tbody>
</table>

---

1st IACM VIRTUAL CANNABIS CONFERENCE 2020 • SPONSORING & EXHIBITION INVITATION

05 OCTOBER 2020 • 07 NOVEMBER 2020 • ONLINE • WORLDWIDE
Booth Visuals

Exhibition Hall

Virtual Booth Medium Template choices

Virtual Booth Small Template

Virtual Booth Large Template choices

To see how the virtual booths look when in use, please visit our demo site: https://emea.6connex.com/event/congrex/login?return=Outside
Sponsorship Opportunities

Companies may support the IACM Congress by many sponsorship opportunities. Sponsors may compile their individual sponsorship packages in addition to the given benefits included, in order to reach the requested sponsorship level. However, sponsorship is not restricted to major packages; companies may also take up sponsorship of one of the individual sponsorship items.

Contact:
Benedict Adam
Congrex Switzerland Ltd.
E: industry.iacm@congrex.com
T: +41 61 686 77 18

Rules and Regulations

AMENDMENTS TO THE RULES
Any matters not specifically covered by the preceding rules shall be subject solely to the decision of the organiser. These rules may be amended at any time by the organiser and all amendments so made shall be binding on exhibitors and sponsors equally with the foregoing rules and regulations.

CONDITIONS OF PAYMENT
Conditions of payment mentioned on the invoice / confirmation are valid. In any case the payment has to be made 2 weeks after invoicing and before the start of the event; if not, the participation cannot be guaranteed and the rental fee remains due.
All published prices are in Euro (EUR).

CANCELLATION
After having signed the sponsorship contract, the company will receive the respective invoice. When a booking is cancelled, a cancellation fee of 100% is due.

PLACE OF LEGAL PERFORMANCE AND VENUE
Should the parties involved disagree on any point, they are subject to the official court of Basel-Stadt, Switzerland, thus Swiss law will be applied.